+91-8668442535

Hepatitis C Treatment Market By Drug Type (Interferons, Ribavirin, Direct-Acting Antivirals (DAA) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Hepatitis C is an inflammatory disease of the liver caused by infection with the hepatitis C virus (HCV). The increasing prevalence of hepatitis C, improved diagnostic techniques, easy availability of treatment medication, and the strong presence of pipeline molecules are driving the growth of the hepatitis C treatment market globally.

The report titled "Hepatitis C Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall hepatitis C treatment market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on drug type and different geographical regions.

Geographically, the global hepatitis C treatment market is studied for the following regional markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of LATAM
  • Middle East and Africa
  • GCC
  • the remainder of MEA

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global hepatitis C treatment market. In-depth analysis of pipeline molecules for key products, such as hepatitis C treatment, and global epidemiology data for hepatitis C have been included in the report. Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive landscape of the global hepatitis C treatment market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global hepatitis C treatment market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global hepatitis C treatment market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on drug type, the global hepatitis C treatment market is segmented as follows:

  • Interferons
  • Peginterferon alfa-2a
  • Peginterferon alfa-2b
  • Interferon alfa-2b
  • Ribavirin
  • Direct-acting antivirals (DAA)
  • Protease Inhibitor
  • Paritaprevir
  • Simeprevir
  • Grazoprevir
  • Polymerase Inhibitors
  • Other Drugs

Hepatitis C is an inflammatory disease of the liver caused by infection with the hepatitis C virus (HCV). The medications and duration of HCV treatment depend on a number of factors, such as genotype (the genetic structure of the virus), viral load, degree of liver damage, and ability to tolerate the prescribed treatment. For the purpose of the study, the hepatitis C treatment market is segmented on the basis of drug types, such as interferons, ribavirin, and direct-acting antivirals. It is studied that direct-acting antivirals (DAA) will show significant market growth during the forecast period due to their safety and effectiveness in the treatment of hepatitis C. DAA is a newer approach to treating hepatitis C, and it increases the chance of cure.

Combinations of tablets have a cure rate of more than 90%. Furthermore, due to its target specificity, DAA has fewer adverse effects in the treatment of hepatitis C. Newly approved medications such as Zepatier (elbasvir/grazoprevir), Epclusa (sofosbuvir/velpatasvir), Mavyret (glecaprevir and pibrentasvir), and Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) are expected to show significant market growth during the forecast period.

For the purpose of this study, the global hepatitis C treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

According to the World Health Organization (WHO), approximately 71 million people have a chronic hepatitis C infection. It is known that, in the base year 2016, North America dominated the region in the hepatitis C treatment market in terms of revenue. Factors such as a large number of target populations, the higher cost of treatment medication, technological advances, improved diagnostic techniques, and an upsurge in funding by government agencies in the healthcare system are assisting the growth of the hepatitis C treatment market in North America. According to the Centers for Disease Control and Prevention (CDC), 2.7–3.9 million people in the United States are infected with chronic hepatitis C. It is observed that currently, Europe is the second largest revenue-generating regional market for hepatitis C treatment due to an increase in the prevalence of the disease and high healthcare awareness. The U.K., Germany, and France are major revenue-contributing countries in Europe. It is anticipated that the Asia Pacific market will grow significantly during the forecast period due to populous countries, developing economic conditions, and improving healthcare infrastructure.

Frequently Asked Question:

The market for Hepatitis C Treatment Market is expected to reach USD$ 65.48 Bn in 2025.

The Hepatitis C Treatment Market is expected to see significant CAGR growth over the coming years, at 11.3%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

AbbieVie Inc.,Bristol-Myers Squibb Company,F. Hoffmann-La Roche AG,Gilead Sciences Inc.are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Sep 2017
Category:  Pharmaceuticals
Report ID:   58653
Report Format:   PDF
Pages:   120
Rating:    4.7 (65)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support